199 results on '"Fallowfield, L."'
Search Results
2. A structured review of quality of life in advanced and high‐risk cutaneous squamous cell carcinoma shows the need for more studies and better measures
3. Digital Health for Optimal Supportive Care in Oncology: Benefits, Limits, and Future Perspectives
4. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)
5. 165MO Patient (pt) preference for the pertuzumab-trastuzumab fixed-dose combination for subcutaneous use (PH FDC SC) in HER2-positive early breast cancer (EBC): Primary analysis of the open-label, randomised crossover PHranceSCa study
6. NICE Guidelines: management of colorectal cancer metastases
7. Digital health for optimal supportive care in oncology: benefits, limits, and future perspectives
8. Summary
9. Abstract ES9-1: Discussing risk & uncertainty with patients in the context of GEP testing
10. Measuring the Quality of Life in Breast Cancer
11. Talking about risk in the context of genomic tests (TARGET): development and evaluation of an educational program for clinicians
12. Effects of neratinib on health-related quality of life in women with HER2-positive early-stage breast cancer: longitudinal analyses from the randomized phase III ExteNET trial
13. How heretical thoughts and challenging orthodoxy improves breast cancer care
14. Treatment Experiences, Information Needs, Pain and Quality of Life in Men with Metastatic Castrate-resistant Prostate Cancer: Results from the EXTREQOL Study
15. 4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)
16. Do drugs offering only PFS maintain quality of life sufficiently from a patient’s perspective? Results from AVALPROFS (Assessing the ‘VALue’ to patients of PROgression Free Survival) study
17. Correction to: 3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
18. Efficacy and safety of subcutaneous trastuzumab and intravenous trastuzumab as part of adjuvant therapy for HER2-positive early breast cancer: Final analysis of the randomised, two-cohort PrefHer study
19. Enhancing decision-making about adjuvant chemotherapy in ER+, HER2- early breast cancer (EBC) following EndoPredict testing
20. Effects of neratinib (N) on health-related quality of life (HRQoL) in early-stage HER2+ breast cancer (BC): longitudinal analyses from the phase III ExteNET trial
21. The cost-effectiveness of EndoPredict to inform adjuvant chemotherapy decisions in early breast cancer
22. Too Hot, Too Cold or Can We Get it Just Right? What Emotional Distance Should Oncologists Keep from their Patients?
23. Corrigendum to “3rd ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 3)” [Breast 31 (February 2017) 244–259]
24. Abstract OT1-03-01: The UK LORIS trial: Randomizing patients with low or low intermediate grade ductal carcinoma in situ (DCIS) to surgery or active monitoring
25. 3rd ESO–ESMO international consensus guidelines for Advanced Breast Cancer (ABC 3)
26. 3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
27. Final results of the TANIA randomised phase III trial of bevacizumab after progression on first-line bevacizumab therapy for HER2-negative locally recurrent/metastatic breast cancer
28. Efficacy and safety of subcutaneous trastuzumab and intravenous trastuzumab as part of adjuvant therapy for HER2-positive early breast cancer: final analysis of the randomised, two-cohort PrefHer study
29. Therapeutic aims of drugs offering only progression-free survival are misunderstood by patients, and oncologists may be overly optimistic about likely benefits
30. No man’s land: information needs and resources of men with metastatic castrate resistant prostate cancer
31. Abstract OT2-02-04: The LORIS trial: A multicentre, randomised phase III trial of standard surgery versus active monitoring in women with newly diagnosed low risk ductal carcinoma in situ
32. Abstract P6-14-01: Final results of the TANIA randomized phase III trial of bevacizumab (BEV) after progression on 1st-line BEV therapy for HER2-negative locally recurrent/metastatic breast cancer (LR/mBC)
33. 3331 Quality of survival (QoS) concept framework to assess the quality of prolonged life in advanced melanoma (MEL): Principles and application related to treatment with nivolumab (NIVO)
34. 1509 Oncologists' decision making about novel therapies for patients with metastatic disease
35. 1542 Gaps and inconsistencies found in information available for men with mCRPC
36. 1715 Patient reported outcome measures for cancer caregivers: A systematic review
37. 1534 Patients' understanding about the therapeutic aims of novel drugs shown only to offer PFS benefit
38. Implications of subcutaneous or intravenous delivery of trastuzumab; further insight from patient interviews in the PrefHer study
39. Effects of Breast Conservation on Psychological Morbidity Associated with Diagnosis and Treatment of Early Breast Cancer
40. The LORIS Trial: Addressing Overtreatment of Ductal Carcinoma In Situ
41. Current Concepts of Communication Skills Training in Oncology
42. Psychosocial/Survivorship Issues in Breast Cancer: Are We Doing Better?
43. NEOCENT: a randomised feasibility and translational study comparing neoadjuvant endocrine therapy with chemotherapy in ER-rich postmenopausal primary breast cancer
44. Words Matter: Distinguishing "Personalized Medicine" and "Biologically Personalized Therapeutics"
45. ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)
46. Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer study
47. ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)
48. Patient Satisfaction with Self-Administration of Subcutaneous (Sc) Trastuzumab Via Single-Use Injection Device (Sid) in the International, Randomised Prefher Study
49. Sexual activity and functioning in ovarian cancer survivors: an internet-based evaluation
50. The need to determine whether lung metastasectomy improves survival in advanced colorectal cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.